Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study
PDF

Letter to the Editor

Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study

Turk J Osteoporos 2023;29(3):184-185 DOI: 10.4274/tod.galenos.2023.24571
,
PDF
Permissions

References

1

Tezel N, Cankurtaran D, Ecerkale Ö, Ünlü Akyüz E. Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study. Turk J Osteoporos 2021;27:159-64.

2

Tsai JN, Lee H, David NL, Eastell R, Leder BZ. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol 2019;7:767-75.

3

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.

4

Prolia FDA Approval History. Available from: URL: https://www.drugs.com/history/prolia.html

5

Moshi MR, Nicolopoulos K, Stringer D, Ma N, Jenal M, Vreugdenburg T. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcif Tissue Int 2023;112:631-46.

6

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513-23.